The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer.

Abstract

Tumor-associated macrophages (TAMs) are pivotal for tumor progression and metastasis. We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC). Two independently clinical cohorts of stage II-III CRC were retrospectively enrolled in this study. TAMs were detected using immunohistochemical staining for CD86 and CD163. The stromal CD86/CD163 ratio was calculated as a prognostic biomarker for recurrence-free survival (RFS) and overall survival (OS). Patients with a low CD86/CD163 ratio had shorter RFS (HR=0.193, p<0.001) and OS (HR=0.180, p<0.001) than patients with a high CD86/CD163 ratio in the training cohort. CD86/CD163 ratio may be an independent predictor for RFS (HR=0.233, p<0.001) and OS (HR=0.224, p<0.001) in the training cohort. We obtained equivalent results in the validation cohort. The CD86/CD163 ratio tends to have better predictive values than tumor stage in the training (AUC: 0.682 vs 0.654, p=0.538) and validation (AUC: 0.697 vs 0.659, p=0.586) cohorts. CD86/CD163 ratio effectively predicts RFS for stage II (HR=0.203, p<0.001) and stage III CRC (HR=0.302, p<0.001). CD86/CD163 ratio also effectively predicts RFS in CRC patients with adjutant chemotherapy (HR=0.258, p<0.001) and without adjutant chemotherapy (HR=0.205, p<0.001). The stromal CD86/CD163 ratio could be used for individual risk assessment of recurrence and mortality for stage II-III CRC. Together with tumor stage, this ratio will aid in the personal treatment.

• Authors: Guozeng Xu, Lei Jiang, Cheng Ye, Guizhen Qin, Zhanxiong Luo, Yuzhen Mo, Jian Chen
• Journal: Frontiers in immunology (Front Immunol) Vol. 12 Pg. 724429 ( 2021) ISSN: 1664-3224 [Electronic] Switzerland
• PMID: 34512652 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Xu, Jiang, Ye, Qin, Luo, Mo and Chen.

Chemical References

• Antigens, CD
• Antigens, Differentiation, Myelomonocytic
• B7-2 Antigen
• CD163 antigen
• Receptors, Cell Surface

Topics

• Aged
• Antigens, CD (metabolism)
• Antigens, Differentiation, Myelomonocytic (metabolism)
• B7-2 Antigen (metabolism)
• Colorectal Neoplasms (metabolism, mortality, pathology)
• Female
• Humans
• Macrophages (metabolism)
• Male
• Middle Aged
• Multivariate Analysis
• Neoplasm Recurrence, Local
• Neoplasm Staging
• Predictive Value of Tests
• Prognosis
• Proportional Hazards Models
• ROC Curve
• Receptors, Cell Surface (metabolism)
• Retrospective Studies
• Risk Assessment